Natera to Report its Third Quarter Results on November 5, 2026

Natera (NTRA) will release its third-quarter financial results after the market closes on November 5, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.

Earnings Conference Call Information
Event:			Natera’s Third Quarter 2026 Financial Results
Date:			November 5, 2026
Time:			4:30 p.m. ET
Live Dial-In:			1-833-461-5787 (Domestic)
			1-585-542-9983 (International)
Conference ID:			221 556 643
Webcast:			https://events.q4inc.com/attendee/221556643

It is recommended that participants pre-register for the call. Pre-registration is available here.

A webcast replay will be available at investor.natera.com.

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029604280/en/

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Source: Natera, Inc.

Key Terms

cell-free dna technical

Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.